

BG SALES-TRADING MORNING DU 21/01/2016

LA SEANCE DE LA VEILLE									
INDICES U.S & JAPON				SECTEURS S&P : BEST PERFS			SECTEURS STOXX : BEST PERFS		
Indices	Cloture	Var %	Var 17h30-22H (en %)	S&P	Var %	YTD	STOXX	Var %	YTD
DJ	15766,7	-1,6%	1,3%	Semi Conducteurs	0,7	-13	Technology	-1,6	-7,8
NASDAQ	4471,7	-0,1%	3,6%	Consumer Durables	0,6	-9,5	Chemicals	-2,4	-12,6
S&P 500	1859,3	-1,2%	1,8%	PHARMA.	0,4	-7,2	Food & BeV	-2,4	-7,4
NIKKEI	16017,3	-2,4%	-	Health Equip.	-0,2	-7	Healthcare	-2,5	-9,7
SECTEURS S&P : WORST PERFS.					SECTEURS STOXX : WORST PERFS				
				S&P	Var %	YTD	STOXX	Var %	YTD
				Real Estate	-3	-8	Basic Resources	-5,2	-21,4
				Oil & Gaz	-2,9	-13,3	Oil & Gas	-5,1	-14,4
				Utilities	-2,3	-0,5	Insurance	-4,5	-12,8
				Banks	-2,1	-15,5	Banks	-4,3	-17,8

Valeurs les plus traitées hier vs. Moy. 3M									
CAC 40			EURO STOXX 50			STOXX 600			
Stocks*	Last	Var%	Stocks*	Last	Var%	Stock*s	Last	Var%	
-	-	-	ASML HOLDING NV	77,2	4,6	AMADEUS IT HOLDING SA-A SHS	36,6	-2,5	
-	-	-	BANCO SANTANDER SA	3,7	-4,8	UBM PLC	490,5	-2	
-	-	-	UNICREDIT SPA	3,7	-7,8	TUI AG-DI	1175	-4,9	
-	-	-	BNP PARIBAS	42,8	-3	-	220	-10,8	
-	-	-	IBERDROLA SA	6,2	-1,3	BOLLORE	3,7	-2,4	

DEFINITION : * compare les capitaux traités sur une valeur la veille rapportés à la moyenne des capitaux traités ces 3 derniers mois sur la valeur.

TAUX U.S				DEVICES				MAT. PREMIERES			
Taux U.S	Valeur	Var%	Yld	Devises	Valeur	Var%	YTD	Mat. Prem	Valeur	Var%	YTD
U.S 2 ANS	100,3	0%	0,8%	€/ \$	1,0912	0,2%	0,5%	BRENT	26,4	-0,1%	-26,3%
U.S 10 ANS	102,4	0%	2%	€/ ¥	127,3	0%	2,6%	ONCE OR (\$)	1104,1	0,3%	4%

VIX Index	27,6	5,9%	VSTOXX Index	35,1	14,2%
-----------	------	------	--------------	------	-------

Economic Calendar

ECB - rate decision (0.05% unchanged exp.)
 ECB - Deposit Facility rate (-0.3% Unch. Exp.)
 US - Philadelphia Fed.
 US - Initial jobless claims Jan. (280K exp.)
 US - DOE inventories

Dividends Calendar ex-date next day

Ex Div today

COMPASS (CPG.L) 19.6p
 SHAFTESBURY (SHB.L) 6.925p
 KERING (PRTP.PA) 1.5€ (1.06%)

Markets Recap (source Street account)

Asian markets are trading higher on Thursday. There has been a improvement in sentiment following the late bounce off the lows in the US overnight. The Nikkei's rebound has coincided with renewed yen weakness, while mainland China has swung into positive territory after the PBoC injected the most liquidity in three years. The yuan mid-point was also fixed slightly lower. Miners are leading gains on the ASX. There has been a solid rebound in commodity currencies with both the kiwi and Aussie recovering Wednesday's losses. Oil has been fairly steady despite API data earlier revealing a larger-than-expected crude inventory build last week.

US equities were mostly lower today, well off worst levels following an afternoon rally. Treasuries were stronger, with the curve flattening somewhat. The dollar was little changed overall, but underperformed against commodity currencies and the yen. Gold was up. Oil declined sharply, with WTI settling (6.7%) and Brent settling (3.1%).

Yet again, there was no specific driver behind today's price action, though sentiment remained

strongly negative. The afternoon bounce fit with the deeply oversold conditions, but there is skepticism about the sustainability of any rebounds. The outlook for China, weak earnings, and policy fatigue remain significant overhangs.

There was no shortage of cautious commentary in the press, with the latest headlines highlighting concerns about sluggish US growth, dampened CEO confidence, and corporate debt defaults. Additionally, today's economic releases were soft, with the CPI and housing starts both coming in below consensus.

Negative sentiment tended to overshadow the day's corporate news. NFLX posted strong international sub numbers, though domestic subs were light. IBM beat on low-quality earnings and disappointed on guidance. GS was helped by lower expenses. GNC and SAVE positively preannounced.

Energy was the worst performer due to the latest oil selloff. REITs were weaker. A&D companies underperformed. Apparel firms were better. Metals and mining companies outperformed. Semis buoyed tech. Healthcare was the best performer on the back of a biotech rally.

Stocks Factor to watch today :

BIOMERIEUX : gives FY 2016 guidance, LFL organic sales growth of 6-8% after 2015 sales rose 7.1% lfl to 1.965bn€

ADECCO : completes 250m€ share buy back programme.

SAINT GOBAIN : and CORNING INC. Announce new joint venture to produce lightweight glazing for the automotive market

COLLECTIS : enters new agreement with CELLforCURE for the cGMP manufacturing of UCART 123

REMY COINTREAU : returned to sales growth in the 3Q driven by demand in the U.S. and improving sales in China.

CARMAT : the 4th patient to have an artificial heart implant died from medical complications

JC DECAUX : and VERIZON WIRELESS had signed a multi year contract to deploy VERIZON's small cells integrated in JCD's U.S. street furniture assets.

Rating & TP Changes



ASML : BUY vs. NEUTRAL, TP 85€ vs. 76 @Bryan Garnier

SOFTWARE AG : TP raised to 27€ vs. 25, Hold @ DBK

CAPGEMINI : added to Conviction Buy List, Buy @Goldman Sachs

SGS : TP raised to 1930CHF vs. 1850, Hold @ SOCGEN



GEMALTO : TP cut to 53€ vs. 54 @Goldman Sachs

ZURICH INSURANCE : TP cut to 295CHF vs. 310, NEUTRAL @Bryan Garnier

ZURICH INSURANCE : TP cut to 275CHF vs. 285, HOLD @ DBK

ZURICH INSURANCE : TP cut to 266CHF vs. 275, @Goldman Sachs

ZURICH INSURANCE : TP cut to 280CHF vs. 305, @Credit Suisse

ZURICH INSURANCE : TP cut to 195CHF vs. 230, @SOCGEN

SGS : TP cut to 1780CHF vs. 1790, Hold @ Jefferies

SANOFI : TP cut to 76€ vs. 78, Hold @Jefferies

DIAGEO : TP cut to 2000p vs. 2100p, BUY @Jefferies

ACCORHOTELS : Underweight vs. Overweight @ Barclays

RWE : TP cut to 10.5€ vs. 11.5, Reduce @ HSBC

EDENRED : Underperform vs. Neutral @ Credit Suisse

Bryan Garnier ... Today's comment(s)

Grandvision	RATING : BUY	Fair Value EUR29,5 vs. EUR29 (+19%)
-------------	--------------	-------------------------------------

Ahead of FY15 results due to be released on 16th March, GrandVision reported this morning its FY15 comparable growth which amounted 4.1%, bang in line with our expectations (BG: +4.1%e). This performance implies a comparable growth of 2.2% in Q4 alone and this sequential deceleration vs. Q3 (+3.7%) was well flagged by investors given a challenging comparison base (+6.1% in Q4 14 vs. +3.8% in Q3) as it carried out intense promotional campaigns last year. We leave our assumptions unchanged, Buy recommendation and FV of EUR29.5 reiterated. => **Positive**

Rémy Cointreau	RATING : BUY	Fair Value EUR72
----------------	--------------	------------------

Rémy Cointreau's Q3 2015/16 sales beat consensus estimates thanks to both the FX and the organic performance of cognac. They amounted to EUR298.4m (CS: EUR294.1m), up 10.9% on a reported basis and 3.2% organically (CS: +2.8% and BG: +2.6%). This is a strong improvement from Q1 and Q2 which were respectively down 9% and 3.2% and was driven by both the cognac and the liqueurs & spirits divisions.

→ positive

Zurich Insurance Group	RATING : NEUTRAL	Fair Value CHF295 vs. CHF310
------------------------	------------------	------------------------------

2015 will definitely be remembered as an annus horribilis for the company, with FY net income now expected at USD2.4bn, down 43% yoy. We also cut our 2016-2017 estimates by 4% and 3% respectively, considering the recovery will take more time than previously expected. Our new FV is CHF295. Yet we still expect the company to announce a special dividend (CHF8) on top of the CHF17 regular dividend, which provides a 11.4% global yield.

ASML	RATING : BUY vs. NEUTRAL	Fair Value EUR85 vs. EUR76
------	--------------------------	----------------------------

Back in September, we initiated ASML with a Neutral recommendation and a FV of EUR77 due to our uncertainties about capex downward revision from largest customers (which has been proven to be real). Today, we believe the clouds will dissipate soon and we recommend investor to look back on the case to take advantage of current weakness on the share price. We think that investments made by foundries to ramp 10nm technology should help to restore a strong momentum from Q2-16e. In addition, the group announced yesterday reassuring achievement about EUV. Our new FV is EUR85 (vs. EUR76) and we upgrade our recommendation to Buy vs. Neutral.

bioMérieux	RATING : BUY	Fair Value EUR121 (+18%)
------------	--------------	--------------------------

BioMérieux reports FY2015 sales standing at EUR1965m (7.1%^{CER}, 15.7%^{reported}), 1% above consensus estimates, driven by a good performance of FilmArray despite weak flu season. As a reminder, the company adjusted its organic growth guidance in Q3 from 4.5%-6.5% to 6.5%. 2015Q4 sales stands at EUR553 (4%^{CER}, 10%^{reported}) slightly affected by a high comparison basis. For FY2016, organic growth guidance came at 6%-8% vs. BGe 6%.
